Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Immuron Ltd ADR is a biotechnology business based in the US. Immuron Ltd ADR shares (IMRN) are listed on the NASDAQ and all prices are listed in US Dollars. Immuron Ltd ADR employs 5 staff and has a trailing 12-month revenue of around $765,193.
Finder Award
eToro
Finder Award
SoFi Invest
| Latest market close | $2.23 |
|---|---|
| 52-week range | $1.39 - $4.27 |
| 50-day moving average | $2.02 |
| 200-day moving average | $2.40 |
| Wall St. target price | $6.41 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.56 |
*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.225 from 2023-01-25
| 1 week (2023-01-19) | 4.71% |
|---|---|
| 1 month (2022-12-23) | 16.49% |
| 3 months (2022-10-26) | 15.89% |
| 6 months (2022-07-26) | -6.51% |
| 1 year (2022-01-26) | -39.70% |
|---|---|
| 2 years (2021-01-26) | -70.49% |
| 3 years (2020-01-23) | 3.46 |
| 5 years (2018-01-26) | 6.73 |
| Revenue TTM | $765,193 |
|---|---|
| Gross profit TTM | $523,502 |
| Return on assets TTM | -7.51% |
| Return on equity TTM | -11.63% |
| Profit margin | 0% |
| Book value | $4.08 |
| Market capitalisation | $12.3 million |
TTM: trailing 12 months
We're not expecting Immuron Ltd ADR to pay a dividend over the next 12 months.
Over the last 12 months, Immuron Ltd ADR's shares have ranged in value from as little as $1.39 up to $4.265. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Immuron Ltd ADR's is 1.3318. This would suggest that Immuron Ltd ADR's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, Israel, Canada, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for support digestive health and gastrointestinal tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) that is in Phase III registration trial to reduce the risk of contracting travelers' diarrhea in the United States, and Phase II field trial for Travelers' Diarrhea, as well as acts as an anti-viral activity against SARS-CoV-2; and IMM-529, which is in Phase I/IIa clinical trial for treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia. .
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Learn about stock analysis and how to use it to find the right company to buy.
